Do A-fib patients continue to benefit from vitamin K antagonists with advancing age?
Metadata[+] Show full item record
Q Do A-fib patients continue to benefit from vitamin K antagonists with advancing age? Evidence-based answer: yes, patients with atrial fibrillation who are between the ages of 50 and 90 years continue to benefit from vitamin K antagonist therapy (warfarin) (strength of recommendation [SOR]: A, meta-analysis of randomized controlled trials [RCTs] and large cohorts). Regardless of age, warfarin produces a reduction in risk of thrombotic events that is 2- to 4-fold greater than the risk of hemorrhagic events.
Journal of Family Practice, vol. 68, no. 6 (July/August 2019), p. E12-E14